1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 30, Issue 3, 2010, Pages 344-348

  Li, Yuandong ^a   Xu, Jun ^a   Zou, Haojun ^a   Wang, Chunyou ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

1 Methyl tryptophan; Foxp3; Indoleamine 2,3 dioxygenase; Pancreatic adenocarcinoma; Treg cells

Indexed keywords

1 METHYL TRYPTOPHAN; 1-METHYL-TRYPTOPHAN; CANCER VACCINE; DRUG DERIVATIVE; TRYPTOPHAN;

ADENOCARCINOMA; ANIMAL; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CYTOLOGY; DENDRITIC CELL; DOWN REGULATION; FEMALE; IMMUNOLOGY; MALE; MOUSE; PANCREAS TUMOR; PATHOLOGY; REGULATORY T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN;

EID: 77956382109     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-010-0354-3     Document Type: Article

References (31)

1. Itoh K, Yamada A, Mine T, et al. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol, 2009, 39(2):73-80
2. Gilboa E. DC-based cancer vaccines. J Clin Invest, 2007, 117(5):1195-203
3. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol, 2006, 17(4):563-570
4. Qiu J, Li GW, Sui YF, et al. Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective antitumor immune response in vivo. World J Gastroenterol, 2006, 12(3):473-478
5. Ohshita A, Yamaguchi Y, Minami K, et al. Generation of tumor-reactive effect or lymphocytes using tumor RNA-introduced dendritic cells in gastric cancer patients. Int J Oncol, 2006, 28(5):1163-1171
6. Dohnal AM, Graffi S, Witt V, et al. Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med, 2009, 13(1):125-135
7. Oh ST, Kim CH, Park M Y, et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine, 2006, 24(15):2860-2868
8. David J, Bettinga XM, Kafia K, et al. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. Vaccine, 2009, 27:250-259
9. Liu XQ, Wang X. Indoleamine 2, 3-dioxygenase in tumor induced tolerance. Chin Med J (Engl), 2009, 122(24):3072-3027
10. Lob S, Konigsrainer A. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg, 2008, 393(6):995-1003
11. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol, 2009, 21(10):1105-1111
12. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281(5380):1191-1193
13. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2, 3-dioxygenase. J Clin Invest, 2004, 114(2):270-279
14. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2, 3-dioxygenase is expressed in the CNS and downregulates autoimmune inflammation. FASEB J, 2005, 19(10):1347-1349
15. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol, 2002, 3(11):1097-1101
16. Yu G, Fang M, Gong M, et al. Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cells. Transpl Immunol, 2008, 18(3):208-219
17. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol, 2004, 4(10):762-774
18. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol, 2003, 24(5):242-248
19. Puccetti P, Fallarino F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. Blood Cells Mol Dis, 2008, 40(1):101-105
20. Belladonna ML, Orabona C, Grohmann U, et al. TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med, 2009, 15(2):41-49
21. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest, 2005, 115(12):3623-3633
22. Wilczynski JR, Radwan M, Kalinka J. The characterization and role of regulatory T cells in immune reactions. Front Biosci, 2008, 13:2266-2274
23. Moo-Young TA, Larson JW, Belt BA, et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother, 2009, 32(1):12-21
24. + regulatory T cells confer infectious tolerance in a TGF-{beta}-dependent manner. J Exp Med, 2008, 205(9):1975-1981
25. + regulatory T cells. Nat Immunol, 2008, 9(6):632
26. - T cells into Foxp3+ induced regulatory T cells. J Immunol, 2009, 182(8):4633-4640
27. Belladonna ML, Volpi C, Bianchi R, et al. Cutting edge: Autocrine TGF-{beta} sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol, 2008, 181(8):5194-5198
28. Ou X, Cai S, Liu P, et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleaminepyrrole 2, 3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol, 2008, 134:525-533
29. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol, 2006, 176(11):6752-6761
30. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine ioxygenase. J Clin Invest, 2007, 117(9):2570-2582
31. Ziske C, Etzrodt PE, Eliu AS, et al. Increase of in vivo antitumoral activity by CD40l (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids. Pancreas, 2009, 38(10):758-765